newsroom

Watch the most recent interview with Prof. Dr. Christoph Wanner's to learn about a breakthrough in CKD therapy. As the Deputy Chair of the EMPA-KIDNEY Trial, Prof. Dr. Wanner discusses how the SGLT2-inhibitor, Empagliflozin, has significantly decreased the risk of progression of renal failure and cardiovascular death compared to placebo. The study was even terminated early due to the benefit of the drug. Discover the potential benefits of this new drug and watch Life/insights#1: New CKD therapeutics